Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
Completed · Phase 1
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib after an autologous peripheral blood stem cell transplant may stop the growth of any cancer cells that remain after transplant. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib in treating patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant.
Key facts
- Study ID
- NCT00288028
- Run by
- Barbara Ann Karmanos Cancer Institute
- People needed
- 15
- Starts
- 2005-07-01
- Expected to finish
- 2012-06-01
- Last updated by the study team
- 2013-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.